Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors.

Anticancer research - 1 Sept 2026

Marchese Paola Valeria, Zannini Irene, DE Biase Dario, Corti Barbara, Dika Emi, Ferracin Manuela, Durante Giorgio, Melotti Barbara, Tallini Giovanni, Maloberti Thais, Comito Francesca

Abstract excerpt

BACKGROUND/AIM: Advanced melanoma treatment remains debated, particularly in patients with B-Raf proto-oncogene serine/threonine kinase (BRAF) V600 mutations eligible for both immune checkpoint inhibitors (ICI) and BRAF/MEK inhibitors. Additional biomarkers are needed to improve treatment selection. Mutations of the telomerase reverse transcriptase (TERT) promoter are frequent in melanoma, although their clinical...

Read the complete abstract on PubMed

Topics

Humans
Telomerase
Melanoma
Proto-Oncogene Proteins B-raf
Proto-Oncogene Mas

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Male

Mutation

Promoter Regions, Genetic

Immune Checkpoint Inhibitors

Protein Kinase Inhibitors

Female

Middle Aged

Aged

Retrospective Studies

Adult

Aged, 80 and over

Mitogen-Activated Protein Kinase Kinases

Progression-Free Survival

Source

Identifiers

PMID: 42674721
DOI: 10.21873/anticanres.18351

Genes

TERT
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors.PMID 42674721Read ↗

TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.Semantic proximity Read ↗

<scp><i>TERT</i></scp> promoter mutations in melanoma survivalSemantic proximity Read ↗

TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma PatientsSemantic proximity Read ↗

TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis.Semantic proximity Read ↗

TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated MelanomaSemantic proximity Read ↗

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.Semantic proximity Read ↗

TERT mutations in Malignant Melanoma-Survival Meta-AnalysisSemantic proximity Read ↗

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.Semantic proximity Read ↗

TERT Promoter Mutations and Telomerase in MelanomaSemantic proximity Read ↗

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases.Semantic proximity Read ↗

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.Semantic proximity Read ↗

TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.